Protein nanoparticles for intracellular delivery of therapeutic enzymes

Journal of Pharmaceutical Sciences

Volumn 103, Issue 6, 2014, Pages 1863-1871

  Estrada, Lina Herrera ^a   Chu, Stanley ^a   Champion, Julie A ^a  

^a Georgia Institute of Technology   (United States)

Author keywords

cross linking; desolvation; enzyme activity; intracellular delivery; macromolecular drug delivery; nanoparticles; particle size; protein delivery; therapeutic enzymes

Indexed keywords

BETA GALACTOSIDASE; CELL PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; IMIDAZOLE; NANOPARTICLE; PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME ACTIVITY; ENZYME THERAPY; FLUORESCENCE; GM1 GANGLIOSIDOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; MORQUIO SYNDROME; NONHUMAN; PARTICLE SIZE; CHEMISTRY;

BETA-GALACTOSIDASE; NANOPARTICLES; PARTICLE SIZE; PROTEINS;

EID: 84901262689     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23974     Document Type: Article

References (53)

1. Holcenberg JS, Roberts J,. 1977. Enzymes as drugs. Ann Rev Pharm 17: 97-116.
2. Holcenberg JS,. 1982. Enzyme therapy: Problems and solutions. Ann Rev Biochem 51: 795-812.
3. Vellard M,. 2003. The enzyme as drug: Application of enzymes as pharmaceuticals. Curr Opin Biotechnol 14: 444-450.
4. Torchilin V,. 2008. Intracellular delivery of protein and peptide therapeutics. Drug Discov Today Technol 5 (2-3): e95-e103.
5. Richard E, Douillard-Guilloux G, Cailaud C,. 2011. New insights into therapeutic options for Pompe diseases. Life 63 (11): 979-986.
6. Yang Y, al. e. 2013. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Am Assoc Cancer Res 67: 9472-9481.
7. Cutler NR,. 2001. Review of the next generation of Alzheimer's disease therapeutics: Challenges for drug development. Prog Neuropsychopharmacol Biol Psychiatry 25 (1): 27-57.
8. Sowa ME, Bennet EJ, Gygi SP, Harper JW,. 2009. Defining the human deubiquitinating enzyme interaction landscape. Cell 138 (2): 389-403.
9. Borodovsky A, Ovaa H, Kolli N, Gan-Erdene T, Wilkinson KD, Ploegh HL, Kessler BM,. 2002. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem Biol 9: 1149-1159.
10. Ludlow JW, Glendening CL, Livingston DM, DeCaprio JA,. 1993. Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol Cell Biol 13 (1): 367-372.
11. Winkler S, Wilson D, Kaplan DL,. 2000. Controlling β-sheet assembly in genetically engineered silk by enzymatic phosphorylation/dephosphorylation. Biochemistry 39 (41): 12739-12746.
12. Gu Z, Biswas A, Zhao M, Tang Y,. 2011. Tailoring nanocarriers for intracellular protein delivery. Chem Soc Rev 40: 3638-3655.
13. Farokhzad OC, Langer R,. 2009. Impact of nanotechnology on drug delivery. ACS Nano 3 (1): 16-20.
14. Win KY, Feng SS,. 2005. Effects of particle size and surface coating on cellular uptakeof polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26: 2713-2722.
15. LaVan DA, McGuire T, Langer R,. 2003. Small-scale systems for in vivo delivery. Nat Biotechnol 21 (10): 1188-1191.
16. Shi J, Votruba AR, Farokhzad OC, Langer R,. 2010. Nanotechnology in drug delivery and tissue engineering: From discovery to applications. Nano Lett 10: 3223-3230.
17. Zhao M, Biswas A, Hu B, Joo K, Wang P, Z. G, Tang Y,. 2011. Redox-resopnsive nanocapsules for intracellular protein delivery. Biomaterials 32: 5223-5230.
18. Koo OM, Rubinstein I, Onyuksel H,. 2005. Role of nanotechnology in targeted drug delivery and imaging: A concise review. Nanomed Nanotechnol Biol Med 1: 193-212.
19. Ganta S, Devalapally H, Shahiwala A, Amiji M,. 2008. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 126: 187-204.
20. Slowing II, Trewyn BG, Giri S, Lin VS-Y,. 2007. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv Funct Mat 17: 1225-1236.
21. Chen YP, Chen C-T, Hung Y, Chou C-M, Liu T-P, Liang M-R, Chen C, Mou C-Y,. 2013. A new strategy for intracellular delivery of enzyme using mesoporous silica nanoparticles: Superoxide dismutase. J Am Chem Soc 135: 1516-1523.
22. Simone EA, Dziubla TD, Colon-Gonzalez F, Discher DE, Muzykantov VR,. 2007. Effect of polymer amphiphilicity on loading of therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules 8 (12): 3914-3921.
23. Boado RJ, Zhang Y, Zhang Y, Xia C-X, Wang Y, Pardridge WM,. 2008. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng 99 (2): 475-484.
24. Karajanagi SS, Vertegel AA, Kane RS, Dordick JS,. 2004. Structure and function of enzyme adsorbed onto single-walled carbon nanotubes. Langmuir 20: 11594-11599.
25. Biswas A, Joo K, Liu J, Zhao M, Fan G, Wang P, Gu Z, Tang Y,. 2011. Endoprotease-mediated intracellular protein delivery using nanocapsules. ACS Nano 5 (5): 1385-1394.
26. Cronican JJ, Thompson DB, Beier KT, McNaughton BR, Cepko CL, Liu DR,. 2010. Potent delivery of functional proteins into mammalian cells in vitro and in vivo using a supercharged protein. ACS Chem Biol 5 (8): 747-752.
27. Stolnik S, Shakesheff K,. 2009. Formulations for delivery of therapeutic proteins. Biotechnol Lett 31: 1-11.
28. Rubino OP, Kowalsky R, Swarbrick J,. 1993. Albumin microspheres as a drug delivery system: Relation among turbidity ratio, degree of cross-linking, and drug release. Pharm Res 10 (7): 1059-1065.
29. Hawkins MJ, Soon-Shiong P, Desai N,. 2008. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60: 876-885.
30. Langer K, Balthasar S, Vogel V, Dinauer N, Von Briesen H, Schubert D,. 2003. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257: 169-180.
31. Gunasekaran S, Sanghoon K, Xiao L,. 2007. Use of whey proteins for encapsulation and controlled delivery applications. J Food Eng 83: 31-40.
32. Biman BM, Kundu SC,. 2009. Self assembled silk sericin/poloxamer nanoparticles as nanocarriers of hydrophobic and hydrophilic drugs for targeted delivery. Nanotechnology 20 (35): 355101.
33. Ren D, Kratz F, Wang SW,. 2011. Protein nanocapsules containing doxorubicin as a pH-responsive delivery system. Small 7 (8): 1051-1060.
34. Kratz F., 2008. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles J Control Release 132: 171-183.
35. Elzohghby AO, Samy WM, Elgindy NA,. 2012. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157: 168-172.
36. Wang G, Siggers K, Zhang S, Jiang HX, Xu Z, Zernicke RF,. 2008. Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm Res 25 (12): 2896-2909.
37. Won YW, Kim YH,. 2008. Recombinant human gelatin nanoparticles as a protein drug carrier. J Control Release 127: 154-161.
38. Ovadia H, Carbone AM, Paterson PY,. 1982. Albumin magnetic microspheres: A novel carrier for Myelin basic protein. J Immunol Methods 53 (1): 109-122.
39. Sinha VR, Trehan A,. 2003. Biodegradable microspheres for protein delivery. J Control Release 90 (3): 261-280.
40. Pechenov S, Shenoy B, Yang MX, Basu SK, Margolin AL,. 2004. Injectable controlled release formulations incorporating protein crystals. J Control Release 96: 149-158.
41. Roy JJ, Abraham TE,. 2004. Strategies in making cross-linked enzyme crystals. Chem Rev 104 (9): 3705-3721.
42. Sharma S, Shrivastav A, Gupta N, Srivastava S,. 2011. Amperometric biosensor: Increased sensitivity using enzyme nanoparticles int conf nanotech biosens. IACSIT Press, Singapore, 24-27.
43. Hoogeven AT, Graham-Kawashima H, d'Azzo A, Galjaard H,. 1984. Processing of human beta-galactosidas in GM1-gangliosidosis and Morquio B syndrome. J Biol Chem 259: 1974-1977.
44. Weber C, Coester C, Kreuter J, Langer K,. 2000. Desolvation process and surface characterization of protein nanoparticles. Int J Pharm 194: 91-102.
45. Mehravar R, Jahanshahi M, Saghatoleslami N,. 2009. Production of biological nanoparticles from lactalbumin for drug delivery and food science application. Afr J Biotech 8 (24): 6822-6827.
46. Munishkina LA, Ahmad A, Fink AL, Uversky VN,. 2008. Guiding protein aggregation with macromolecular crowding. Biochemistry 47 (34): 8993-9006.
47. Migneault I, Dartiguenave C, Bertrand MJ, Waldron K,. 2004. Glutaraldehyde: Behavior in aqueous solution, reaction with proteins, and application to enzyme crosslinking. Biotechniques 37: 790-802.
48. Dooley C, Dore TM, Hanson GT, Jackson WC, Remington SJ, Tsien RY,. 2004. Imaging dynamic redox changes in mammalian cells with green fluorescent protein indicators. J Biol Chem 279 (21): 22284-22293.
49. Hamilton S, Odili J, Pacifico MD, Wilson GD, Kupsch JM,. 2003. Effect of imidazole on the solubility of a his-tagged antibody fragment. Hybrid Hybrid 22 (6): 347-355.
50. Langer K, Anhorn MG, Steinhauser I, Dreis S, Celebi D, Schrickel N,. 2008. Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm 347: 109-117.
51. Lieleg O, Baumgartel RM, Bausch AR,. 2009. Selective filtering of particles by the extracellular matrix: An electrostatic bandpass. Biophys J 97: 1569-1577.
52. Weigel PH, Oka JA,. 1981. Temperature dependence of endocytosis mediated by the asialoglycoprotein receptor in isolated rat hepatocytes. J Biol Chem 256: 2615-2617.
53. Silverstein SC, Steinman RM, Cohn ZA,. 1977. Endocytosis. Ann Rev Biochem 46: 669-722.